已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Medications for Obesity

医学 利拉鲁肽 减肥 奥利斯特 不利影响 肥胖 芬特明 安非他酮 恶心 食欲 2型糖尿病 内科学 内分泌学 糖尿病 戒烟 病理
作者
Kimberly A. Gudzune,Robert F. Kushner
出处
期刊:JAMA [American Medical Association]
卷期号:332 (7): 571-571 被引量:216
标识
DOI:10.1001/jama.2024.10816
摘要

Importance: Obesity affects approximately 19% of women and 14% of men worldwide and is associated with increased morbidity. Antiobesity medications (AOMs) modify biological processes that affect appetite and significantly improve outcomes, such as type 2 diabetes, hypertension, and dyslipidemia. Observations: AOMs should be administered in combination with lifestyle interventions and can be classified according to their mechanisms of action. Orlistat modifies digestive tract absorption and causes gastrointestinal adverse effects, such as oily fecal spotting and urgency, in more than 25% of patients. Centrally acting drugs, such as phentermine-topiramate and naltrexone-bupropion, regulate appetite in the brain and are associated with constipation in approximately 20% of patients, although the incidence of other adverse effects (eg, paresthesia, nausea) varies by medication. Nutrient-stimulated hormone-based medications, such as liraglutide, semaglutide, and tirzepatide, mimic the actions of enteropancreatic hormones that modify central appetite regulation and provide multiple cardiometabolic weight-loss benefits. Adverse effects of these drugs include nausea (28%-44%), diarrhea (21%-30%), and constipation (11%-24%). The relative potency of adult obesity medications has been studied in meta-analyses. Compared with placebo, orlistat was associated with 3.1% greater weight loss (52 randomized clinical trials [RCTs]; 16 964 participants), phentermine-topiramate was associated with 8.0% greater weight loss (5 RCTs; 3407 participants), naltrexone-bupropion was associated with 4.1% greater weight loss (6 RCTs; 9949 participants), liraglutide was associated with 4.7% greater weight loss (18 RCTs; 6321 participants), semaglutide was associated with 11.4% greater weight loss (5 RCTs; 4421 participants), and tirzepatide 15 mg was associated with 12.4% greater weight loss (6 RCTs; 1972 participants). Conclusion and Relevance: Obesity is associated with increased morbidity. Antiobesity medications are effective adjunctive therapy to lifestyle changes for improved weight loss and health outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
英姑应助long采纳,获得30
刚刚
哈哈哈完成签到 ,获得积分10
1秒前
天真的夏云完成签到,获得积分10
1秒前
大琪哥哥要顺利毕业完成签到 ,获得积分10
3秒前
3秒前
打打应助小徐采纳,获得10
4秒前
霍紫菡发布了新的文献求助10
4秒前
科研通AI6.4应助冰冰宝采纳,获得10
4秒前
思源应助LLLucen采纳,获得10
5秒前
Dean应助Zyd采纳,获得50
5秒前
科研通AI6.3应助1121采纳,获得10
5秒前
天天快乐应助大方岩采纳,获得10
6秒前
Adler发布了新的文献求助10
8秒前
8秒前
创不可贴完成签到,获得积分10
11秒前
isojso发布了新的文献求助10
13秒前
15秒前
15秒前
16秒前
年年完成签到,获得积分10
16秒前
李健应助默默冷亦采纳,获得10
16秒前
Nole应助baboon222采纳,获得10
18秒前
19秒前
科目三应助翁宇轩采纳,获得10
19秒前
LLLucen发布了新的文献求助10
20秒前
JW发布了新的文献求助10
20秒前
慕青应助cc采纳,获得10
20秒前
22秒前
22秒前
顾矜应助Adler采纳,获得10
24秒前
李法拉完成签到 ,获得积分10
24秒前
26秒前
早安地球完成签到,获得积分10
27秒前
LLLucen完成签到,获得积分10
27秒前
27秒前
27秒前
29秒前
30秒前
克米关注了科研通微信公众号
31秒前
三岁半完成签到,获得积分10
31秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Arthritis and Related Conditions, An Issue of Orthopedic Clinics 1000
Development of a Bridge Weigh-In-Motion System: A technology to convert the bridge response to the passage of traffic into data on vehicle configurations, speeds, times of travel and weights 1000
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7288914
求助须知:如何正确求助?哪些是违规求助? 8908529
关于积分的说明 18854981
捐赠科研通 6957365
什么是DOI,文献DOI怎么找? 3208972
关于科研通互助平台的介绍 2378712
邀请新用户注册赠送积分活动 2184750